152 related articles for article (PubMed ID: 14650176)
1. [CCR5, a new target of anti-HIV drugs].
Han YX; Jiang JD
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Oct; 25(5):635-9. PubMed ID: 14650176
[TBL] [Abstract][Full Text] [Related]
2. HIV chemokine receptor inhibitors as novel anti-HIV drugs.
Princen K; Schols D
Cytokine Growth Factor Rev; 2005 Dec; 16(6):659-77. PubMed ID: 16005254
[TBL] [Abstract][Full Text] [Related]
3. Quantifying the relationship between HIV-1 susceptibility to CCR5 antagonists and virus affinity for antagonist-occupied co-receptor.
Buontempo PJ; Wojcik L; Buontempo CA; Ogert RA; Strizki JM; Howe JA; Ralston R
Virology; 2009 Dec; 395(2):268-79. PubMed ID: 19846188
[TBL] [Abstract][Full Text] [Related]
4. Identification of peptide ligands to the chemokine receptor CCR5 and their maturation by gene shuffling.
Vyroubalova EC; Hartley O; Mermod N; Fisch I
Mol Immunol; 2006 Apr; 43(10):1573-8. PubMed ID: 16280164
[TBL] [Abstract][Full Text] [Related]
5. CCR5 antagonists: a new tool in fighting HIV.
Jülg B; Goebel FD
J HIV Ther; 2005 Dec; 10(4):68-71. PubMed ID: 16519245
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of CCR5-mediated infection by diverse R5 and R5X4 HIV and SIV isolates using novel small molecule inhibitors of CCR5: effects of viral diversity, target cell and receptor density.
Willey S; Peters PJ; Sullivan WM; Dorr P; Perros M; Clapham PR
Antiviral Res; 2005 Nov; 68(2):96-108. PubMed ID: 16157392
[TBL] [Abstract][Full Text] [Related]
7. What's New in HIV/AIDS? Chemokine receptor antagonists: a new era of HIV therapy?
Jülg B; Goebel FD
Infection; 2005 Oct; 33(5-6):408-10. PubMed ID: 16258879
[TBL] [Abstract][Full Text] [Related]
8. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro.
Maeda K; Nakata H; Koh Y; Miyakawa T; Ogata H; Takaoka Y; Shibayama S; Sagawa K; Fukushima D; Moravek J; Koyanagi Y; Mitsuya H
J Virol; 2004 Aug; 78(16):8654-62. PubMed ID: 15280474
[TBL] [Abstract][Full Text] [Related]
9. CCR5 antagonists: host-targeted antiviral agents for the treatment of HIV infection, 4 years on.
Westby M; van der Ryst E
Antivir Chem Chemother; 2010 Apr; 20(5):179-92. PubMed ID: 20413825
[TBL] [Abstract][Full Text] [Related]
10. [Chemokine receptors and its importance in the replication cycle of human immunodeficiency virus: clinical and therapeutic implications].
Azevedo-Pereira JM; Santos-Costa Q
Acta Med Port; 2008; 21(5):497-504. PubMed ID: 19187693
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of HIV-1 infection by synthetic peptides derived CCR5 fragments.
Imai M; Baranyi L; Okada N; Okada H
Biochem Biophys Res Commun; 2007 Feb; 353(4):851-6. PubMed ID: 17210123
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and biological evaluation of the combinatorial library with a new spirodiketopiperazine scaffold. Discovery of novel potent and selective low-molecular-weight CCR5 antagonists.
Habashita H; Kokubo M; Hamano S; Hamanaka N; Toda M; Shibayama S; Tada H; Sagawa K; Fukushima D; Maeda K; Mitsuya H
J Med Chem; 2006 Jul; 49(14):4140-52. PubMed ID: 16821774
[TBL] [Abstract][Full Text] [Related]
13. The chemokine system and CCR5 antagonists: potential in HIV treatment and other novel therapies.
Dhami H; Fritz CE; Gankin B; Pak SH; Yi W; Seya MJ; Raffa RB; Nagar S
J Clin Pharm Ther; 2009 Apr; 34(2):147-60. PubMed ID: 19250135
[TBL] [Abstract][Full Text] [Related]
14. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D).
Marozsan AJ; Kuhmann SE; Morgan T; Herrera C; Rivera-Troche E; Xu S; Baroudy BM; Strizki J; Moore JP
Virology; 2005 Jul; 338(1):182-99. PubMed ID: 15935415
[TBL] [Abstract][Full Text] [Related]
15. Peptide, peptidomimetic and small-molecule drug discovery targeting HIV-1 host-cell attachment and entry through gp120, gp41, CCR5 and CXCR4.
Kazmierski WM; Kenakin TP; Gudmundsson KS
Chem Biol Drug Des; 2006 Jan; 67(1):13-26. PubMed ID: 16492145
[TBL] [Abstract][Full Text] [Related]
16. CCR5 antagonists for the treatment of HIV.
Barber CG
Curr Opin Investig Drugs; 2004 Aug; 5(8):851-61. PubMed ID: 15600241
[TBL] [Abstract][Full Text] [Related]
17. Chemokines and chemokine receptors in HIV infection: role in pathogenesis and therapeutics.
Suresh P; Wanchu A
J Postgrad Med; 2006; 52(3):210-7. PubMed ID: 16855325
[TBL] [Abstract][Full Text] [Related]
18. The current status of, and challenges in, the development of CCR5 inhibitors as therapeutics for HIV-1 infection.
Maeda K; Nakata H; Ogata H; Koh Y; Miyakawa T; Mitsuya H
Curr Opin Pharmacol; 2004 Oct; 4(5):447-52. PubMed ID: 15351348
[TBL] [Abstract][Full Text] [Related]
19. Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favourable synergism with anti-CCR5 inhibitors.
Yoshimura K; Shibata J; Kimura T; Honda A; Maeda Y; Koito A; Murakami T; Mitsuya H; Matsushita S
AIDS; 2006 Oct; 20(16):2065-73. PubMed ID: 17053352
[TBL] [Abstract][Full Text] [Related]
20. Chemokine receptor-5 (CCR5) is a receptor for the HIV entry inhibitor peptide T (DAPTA).
Polianova MT; Ruscetti FW; Pert CB; Ruff MR
Antiviral Res; 2005 Aug; 67(2):83-92. PubMed ID: 16002156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
